Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01 (carton) NDC 65250-001-01 (vial) with Diluent 5 mL Sterile single-use vial, Rx Only, Mfd. for: Pacira Pharmaceuticals, Inc. NDC 65250-002-01
Published July 3, 2024 · Recall initiated: June 12, 2024
Summary
FDA records drug Class II recall D-0567-2024, published July 3, 2024 and initiated June 12, 2024. Recalling firm: PACIRA PHARMACEUTICALS INC; Status: Ongoing; Reported quantity: 40,517 kits; Lot: Lot 23-9006; Expiry Date: MAR 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8®C followed by 6 weeks at 25®C
What to do
Voluntary: Firm initiated · Letter
Get an email if ZILRETTA has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ZILRETTA
- Manufacturer
- PACIRA PHARMACEUTICALS INC
- Distributor
- US Nationwide.
- Lot
- Lot 23-9006; Expiry Date: MAR 2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAExtra Strength Acetaminophen 500 MG Tablets,100-count Bottle, Distributed By: MAJOR PHARMACEUTICALS, 17177 NJuly 3, 2024
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90July 3, 2024
- FDALabetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose Carpuject, Sterile CartridgeJuly 3, 2024
- FDASinuFrin Decongestant (oxymetazoline HCl) Nasal Solution Nasal Decongestant, Decongestant Relief for up to 12July 3, 2024
- FDABuprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit withJuly 3, 2024
- FDADrug Vial Label: Zilretta® (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial,June 19, 2024
Questions about this recall
Was Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: Pacira Pharmaceuticals Inc., San Diego, CA 92121, NDC 65250-003-01 (carton) NDC 65250-001-01 (vial) with Diluent 5 mL Sterile single-use vial, Rx Only, Mfd. for: Pacira Pharmaceuticals, Inc. NDC 65250-002-01 recalled?
Yes. FDA published recall D-0567-2024 on July 3, 2024. Reported hazard: Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8®C followed by 6 weeks at 25®C
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ZILRETTA.